MT027 not checked
Suzhou Maximum Bio-tech Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “MT027 will be injected intracerebroventricularly at a dose of 3×10\^7 cells on Day 1 \& Day 15 of each 28-day treatment cycle.”In the company’s words, NCT07386002 on ClinicalTrials.gov
- Tested for
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Brain Metastases From Solid Tumors, Brain (Nervous System) Cancers, Brain and Central Nervous System Tumors, Brain Tumors, Advanced Malignant Solid Tumor, Malignant Pleural Effusion, Pleura Carcinoma and 4 more
- Main trialPhase 2
- “This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4), who have previously received standard of care (SOC) therapy. Each participant will undergo screening, treatment (receiving MT027 at a dose of 3×10\^7 cells), safety follow-up, and long-term follow-up periods. MT027 will be given via ICV injection on Day 1 \& Day 15 of the first 28-day cycle. If the participant does not experience any unacceptable toxicities and…”In the company’s words, NCT07386002 on ClinicalTrials.gov
Other drugs for Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up2
- 13 Dec 2028Phase 2 trial completes · ClinicalTrials.gov
- 20 Dec 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 13 Dec 2028 | The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma | |
| Phase 2Not yet recruiting | 20 Dec 2029 | The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid Tumors | |
| Phase 1Not yet recruiting | 30 Dec 2025 | Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors | |
| Phase 1Recruiting | May 2026 | A Study of MT027 in Patients with Pleural Malignant Tumors | |
| Phase 1Not yet recruiting | 30 Jun 2026 | Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026